STOCK TITAN

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

ALX Oncology Holdings (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing cancer therapies, has announced it will release its first quarter 2025 financial results on Thursday, May 8th, 2025, before the market opens. The company has specified that it will not hold a conference call to discuss the results.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+3.34%
1 alert
+3.34% News Effect

On the day this news was published, ALXO gained 3.34%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.

The company will not be hosting a teleconference in conjunction with its financial results press release.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577


FAQ

When will ALXO release its Q1 2025 earnings?

ALX Oncology (ALXO) will release its Q1 2025 financial results on Thursday, May 8th, 2025, before market open.

Will ALX Oncology host a conference call for Q1 2025 earnings?

No, ALX Oncology will not be hosting a teleconference in conjunction with its Q1 2025 financial results release.

What type of company is ALXO?

ALX Oncology is a clinical-stage biotechnology company that develops novel therapies designed to treat cancer and extend patients' lives.

What is ALX Oncology's stock symbol?

ALX Oncology trades on the Nasdaq under the symbol ALXO.
Alx Oncology Holdings Inc

NASDAQ:ALXO

ALXO Rankings

ALXO Latest News

ALXO Latest SEC Filings

ALXO Stock Data

289.95M
120.03M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO